UNSPSC 51292021: Dapoxetine hydrochloride

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C21H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4OHT63MRI, chemically known as (+)-(s)-n,n-dimethyl-alpha-(2-(1-naphthyloxy)ethyl)benzylamine hydrochloride but more generally known as dapoxetine hydrochloride, which bears US NIH Compound Identifier 71352.

UNSPSC 51292021 Dapoxetine hydrochloride is a Commodity code for a pharmaceutical product, but state and local procurement activity under this code shows no recent opportunities aligned with dapoxetine itself. The single recent opportunity tagged to this code—Seminole County, Florida's IFB60459723LAS for naloxone and drug deactivation systems—represents a significant mismatch with the code's nominal scope. Naloxone (a opioid antagonist used for overdose reversal) and safe drug deactivation systems are distinct public health products with different clinical and operational purposes than dapoxetine (a premature ejaculation treatment), and the county's procurement does not reference dapoxetine as part of its requirement.

Seminole County posted the naloxone and drug deactivation systems IFB on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida; the response deadline was July 26, 2023. The code shows little relevant recent activity for dapoxetine itself among state and local buyers. Firms pursuing pharmaceutical supply opportunities under this code should verify the actual product requirements in sourcing notices before bidding, as category tagging misalignment appears common in this family.